Facebook
X
LinkedIn
Forward
Diabetic Cardiac Protection: Translating Guidelines into Practice
Activity Description
Despite results of major cardiovascular outcomes trials and updates in professional guidelines, evidence-based therapies for cardiovascular risk reduction are generally underused among patients with type 2 diabetes and ASCVD. This course will examine the multifaceted interventions that are needed to overcome the large gaps in evidence-based pharmacotherapy use among this population of patients who is at a high risk of adverse outcomes.
Target Audience
Learning Objectives
- Define atherosclerotic cardiovascular disease (ASCVD) as it pertains to diabetes
- Identify risk factors for ASCVD
- Analyze the three pharmacologic categories of cardiac protection treatment
- Apply cardiac protection interventions based on patient-specific factors
| Name | Role | Disclosure of Relevant Financial Relationships with Ineligible Company |
|---|---|---|
Ariana Scalzo Pharmacist | Planner & Speaker | No relevant financial relationship(s) with ineligible companies to disclose |
Nina Beers Pharmacist | Planner | No relevant financial relationship(s) with ineligible companies to disclose |
Alexandra Cuvelier Pharmacist | Planner | No relevant financial relationship(s) with ineligible companies to disclose |
Hina Ghani Pharmacist | Planner | No relevant financial relationship(s) with ineligible companies to disclose |
Kari Muskopf Occupational Therapist | Other licensed training | Planner | No relevant financial relationship(s) with ineligible companies to disclose |
Jacqueline Jin Pharmacist | Planner | No relevant financial relationship(s) with ineligible companies to disclose |
Claire Lauber Nurse | Planner | No relevant financial relationship(s) with ineligible companies to disclose |
Ajay Gupta Physician | Planner | No relevant financial relationship(s) with ineligible companies to disclose |
Opeyemi Ibrahim Pharmacist | Independent Reviewer | No relevant financial relationship(s) with ineligible companies to disclose |
Lynn Haigh Dietitian, Registered | Independent Reviewer | No relevant financial relationship(s) with ineligible companies to disclose |
Disclosures of relevant financial relationships
In accordance with the Accreditation Council for Continuing Medical Education's (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, Centene Institute for Advanced Health Education (Centene Institute) requires all those in control of educational content to disclose their financial relationships with ineligible companies within the prior 24 months. Ineligible companies are defined by the ACCME as companies whose primary business is producing, marketing, selling, re-selling or distributing health care products used by or on patients. Individuals must disclose all financial relationships, regardless of the amount, with ineligible companies and regardless of their view of the relevance of the relationship to the education. Centene Institute ensures that the content is independent of commercial bias.
None of the Centene Institute staff members have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Universal Activity Number UAN JA4008309-0000-23-008-H01-P
Available Credit
- 0.50 ACPE Pharmacy
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC
- 0.50 Attendance/Participation
Since CE boards may have changes in requirements, it is the responsibility of the attendee to verify with their boards if they accept the CEs being offered.
Required Hardware/software
Please ensure you are using the web-browser Chrome and disable any pop-up blocking software.